The strategy notes that, “given the UK market size at around 3% of global pharmaceutical sales, a wholly free-standing system would likely be high cost-both in terms of efficiency and attractiveness to companies who typically apply to the largest markets first. Nevertheless, the report does include a short section devoted to this subject, with a focus on the implications of Brexit for the future regulatory environment in the UK. Over the next 5 years, the NHS should undertake 50 collaborative programs in late-stage clinical trials, real-world data collection or the evaluation of medical devices or diagnosticsīy 2023, the UK should be in the top quartile of comparator countries for speed of adoption and overall uptake of innovative, cost-effective productsĮstablish digital innovation hubs that each provide data across regions of 3-5 million peopleīuild a migration system that facilitates recruitment of the best talent from around the worldĬuriously, regulation is not one of the key themes of the life sciences strategy. Over the next 5 years, attract 10 large (£50-250 million capital investment) and 10 smaller (£10-50 million capital investment) life sciences manufacturing facilitiesĪdopt the Accelerated Access Review’s recommendations to create streamlined national market access routes for health technologies Over the next decade, create 4 UK-based companies with a market capitalization of > £20 billionīoost investment in manufacture and export of high-value health technologies Over the next 5 years, increase by 50% the number of clinical trials and raise the proportion of change-of-practice studies and trials with novel methodologiesĮnsure the tax environment supports growth Increase funding for basic science to ensure the UK is in the upper quartile of OECD R&D investmentĪttract 2,000 new discovery scientists from around the world Over the next decade, create 2-3 entirely new industries in fields such as genomics, diagnostics, digital health technology, artificial intelligence or healthy ageing. Table 1: Core recommendations and strategic goals in the life sciences strategyĮstablish the Health Advanced Research Program (HARP) to undertake large research infrastructure projects and high-risk “moonshot programs” Table 1 summarizes the core recommendations and strategic goals in each of these five areas. The strategy covers five broad themes: the UK’s science base, growth and infrastructure, collaboration between the NHS and industry, the digitalization of healthcare, and ensuring access to the skills needed to support a flourishing life sciences industry. Sir John Bell, is the product of consultation with a range of stakeholders, including the National Health Service (NHS), the Association of the British Pharmaceutical Industry (ABPI), the BioIndustry Association (BIA), the devolved administrations in Scotland, Wales, and Northern Ireland, a range of manufacturers, and charities. The eagerly awaited life sciences strategy commissioned by the UK government avowedly “places an emphasis on putting the UK in a world-leading position to take advantage of the health technology trends of the next 20 years.” The report, prepared by eminent geneticist Prof. Following the unveiling of the UK’ s post-Brexit life sciences strategy, Neil Grubert looks at the measures related to market access, a particular challenge in the UK market, and key to its future success in the sector.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |